Superseded public profile

FDA-approved↗Rare disease↗

Superseded · version 4: Elamipretide↗

Related names recorded in this version: SS-31, MTP-131, Forzinity↗↗

FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We added a preserved FDA-hosted product label to support the product-specific label account. Prior profile versions retain their original citations. 3

What this version reported

FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.↗

Organizations named in cited records:
  • Stealth BioTherapeutics Inc.↗

Trial records: NCT07531251

Sources for this version

  1. 1
    4TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  2. 2
    Forzinity (elamipretide): NDA 215244 accelerated approval letter, September 19, 2025 ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

  3. 3
    FORZINITY, revised September 2025: U.S. prescribing information ↗

    U.S. Food and Drug Administration · Official source · Source checked September 15, 2026